The Subject Expert Committee (SEC) has recommended that Reliance Life Sciences‘ coronavirus vaccine candidate undergo phase 1 clinical trials (Covid-19). According to sources, the suggested vaccine candidate consists of two doses and is based on a recombinant protein platform. The next step for Reliance Life Sciences is to get clearance from the Drugs Controller General of India (DCGI), now that the SEC has recommended phase 1 trials. The firm may begin the first round of clinical studies for its vaccine candidate once the country’s top drug regulator gives authorization.
The Covid vaccine is being developed in the company’s Navi Mumbai plant and would be “competitively priced,” according to the company. During the SEC meeting on Friday, the firm obtained permission. While Reliance Sciences is a Covid-19 testing centre, the exercise will take place in ten locations across India, including Delhi, Maharashtra, Tamil Nadu, and Andhra Pradesh. Phase 1 lasts approximately two months (58 days) and is used to determine the maximum dosages that most patients can take.
Read also: Reliance said to weigh bid for T-Mobile Netherlands: Report
Six vaccinations have received Emergency Use Authorization (EUA) from the DCGI so far, two of which are indigenous, and the others are imported. Sputnik V, Moderna, Johnson & Johnson, and ZyCoV-D were the first two shots to get EUA, followed by Covaxin and Covishield. Vaccines like Covaxin and ZyCoV-D are manufactured in India.
The national immunization campaign against Covid-19 began on January 16 and is open to all citizens over 18. According to the Union health ministry’s dashboard, 612,208,542 doses have been delivered across the country thus far, including 7,948,349 in the previous 24 hours.
Read also: Reliance New Energy Solar to invest in US-based energy storage firm Ambri Inc
Reliance Life Sciences promotes itself as a research-driven company that develops biotherapeutics, medicines, clinical research, molecular medicine, and other commercial prospects. It is part of Mukesh Ambani’s Reliance Industries Limited’s Promoter Group, as the name indicates (RIL).
